Thor Halfdanarson: Functional imaging in neuroendocrine neoplasms
Thor Halfdanarson, Medical Oncologist at Mayo Clinic, shared a post on X about a paper by Odeta Islam et al. published in Endocrine-Related Cancer Journal:
“Functional imaging in NECs and much more… Check out this excellent paper. Lots of goodies in here such as >90% of NECs and G3 NETs FDG PET pos. Also, 66% of NECs pos on SSTR PET. What does that mean? The SSTR is not (yet) a good NEC target.
So far, PRRT has not been shown to be effective in NECs but is highly effective in G3 NETs (NETTER-2). Can we somehow use the presence of the SSTR to target NECs, maybe combining PRRT (alpha better than beta?) with ICIs? What do you think, Timon Vandamme, Willem Lybaert?”
“Management of high-grade neuroendocrine neoplasms: impact of functional imaging”
Authors: Odeta Islam, Kevin Sarti, Lise Verbruggen, Ivan Borbath, Timon Vandamme et al.
More posts featuring Thor Halfdanarson.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023